TABLE 1.
Liposomesb | MLVc
|
FATMLVd
|
LUVETe
|
|||
---|---|---|---|---|---|---|
DCf | ECg | DC | EC | DC | EC | |
MC-Chol-DP | 8.1 ± 2.4 | 5.8 ± 1.6 | 22.7 ± 3.8 | 16.3 ± 2.7 | 21.8 ± 2.6 | 15.7 ± 1.9 |
MC-Chol-PS | 9.2 ± 2.7 | 6.5 ± 2.1 | 28.9 ± 4.3 | 20.8 ± 3.1 | 29.2 ± 5.2 | 21.0 ± 3.7 |
MC-Chol-PE | 5.9 ± 1.8 | 4.3 ± 1.1 | 12.8 ± 3.5 | 9.2 ± 2.5 | 12.4 ± 3.1 | 8.9 ± 2.2 |
MC-Chol-PA | 5.1 ± 2.9 | 3.6 ± 2.2 | 10.1 ± 2.9 | 7.1 ± 1.8 | 10.2 ± 3.3 | 7.3 ± 2.4 |
Each value is the average of five different experiments ± standard deviation.
MC, 1,2-dimyristoyl-sn-glycero-phosphocholine monohydrate; Chol, cholesterol; DP, dihexadecyl hydrogen phosphate; PS, dipalmitoyl-dl-α-phosphatidyl-l-serine; PE, 1,2-dipalmitoyl-sn-glycero-phosphoethanolamine; PA, 1,2-dipalmitoyl-sn-glycero-phosphatidic acid sodium salt.
Multilamellar vesicles (MLV) prepared by lipid film dispersion in isotonic phosphate buffer.
Freeze-and-thaw MLV (FATMLV).
Large unilamellar vesicles (LUVET) obtained from FATMLV by an extrusion technique through polycarbonate membranes.
Drug content (DC) as percentage of drug entrapped within liposomes.
Encapsulation capacity (EC) as microliters of aqueous solution entrapped per micromole of lipids.